Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutations
Abstract Background Recent studies have demonstrated that patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring EGFR mutations (EGFRm) can significantly benefit from adjuvant therapy with EGFR-TKIs. Nevertheless, there remains controversial in clinical practice about the use of EG...
Saved in:
| Main Authors: | Yunyi Li, Zhihui Yang, Fang Wu, Qingchun Liang, James G. Herman, Malcolm V. Brock, Wenliang Liu, Fenglei Yu, Xue He, Chen Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Clinical Epigenetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13148-025-01899-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Review of Plasma Exosomal DNA for Detecting EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Mohammad Mehdi Jahani, et al.
Published: (2025-04-01) -
The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01) -
Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01) -
Identification and external validation of tumor DNA methylation panel for the recurrence risk stratification of stage II colon cancer
by: Tanwei Yuan, et al.
Published: (2025-07-01) -
Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker
by: Meejeong Kim, et al.
Published: (2025-04-01)